667, L.P.
CIK 1551139 · last filed 2026-06-29
667, L.P. is a corporate insider who has filed 88 SEC Form 4 insider transactions across 24 companies since 2013. The most recent filing, for CELC, was dated Jul 14, 2026. Across all open-market trades the lifetime net is +$5.23B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.44B across reported positions. The firm reports its address in New York, NY. 521 SEC filings were submitted jointly with Baker Brothers Life Sciences LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.44B
24
88
$5.23B
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTVT | Director | — | $31.97 | — | $0 | 2 | 2026-06-29 |
| ACAD | Director | 39,487,463 | $27.83 | $1.10B | $630.00M | 3 | 2026-06-02 |
| ONC | Director | 730,643 | $346.51 | $253.18M | -$1.57M | 2 | 2026-05-27 |
| TCRX | Director | — | $0.32 | — | $0 | 3 | 2026-05-22 |
| INCY | Director | 28,482,491 | $121.47 | $3.46B | $0 | 11 | 2026-05-11 |
| REPL | Director | — | $12.92 | — | $0 | 1 | 2026-04-07 |
| DBVT | Director | — | $11.85 | — | $0 | 1 | 2026-01-14 |
| KOD | Director | 18,358,772 | $32.89 | $603.82M | $650.35M | 7 | 2025-12-19 |
| DNLI | Director | — | $21.09 | — | $0 | 1 | 2025-12-15 |
| MDGL | Director | 1,832,216 | $534.49 | $979.30M | $196.74M | 3 | 2025-08-20 |
| IMCR | Director | — | $32.60 | — | $0 | 1 | 2025-05-19 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 355,142 | $1.27 | $451.0K | $0 | 9 | 2025-01-03 |
| BCYC | Director | 8,666,247 | $3.86 | $33.45M | $127.38M | 2 | 2024-12-17 |
| PRLD | Director | — | $4.59 | — | $0 | 2 | 2024-06-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 126,096 | $184.71 | $23.29M | $3.77B | 2 | 2024-06-07 |
| NGNE | Director | 39,081 | $35.48 | $1.39M | $0 | 1 | 2023-12-20 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2023-06-13 |
| KNSA | Director | 132,566 | $76.27 | $10.11M | $0 | 2 | 2023-06-08 |
| Seagen Inc. (SGEN) Delisted | Director | 43,000,581 | $228.74 | $9.84B | $180.65M | 5 | 2023-06-02 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 1 | 2021-05-13 |
| ZYME | Director | — | $26.24 | — | $0 | 1 | 2020-05-12 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 157,519 | — | — | -$482.48M | 10 | 2019-04-12 |
| Aceragen, Inc. (IDRA) Delisted | Director | 9,088 | $7.22 | $65.7K | $224.00M | 4 | 2018-06-21 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 104,451 | $40.17 | $4.20M | -$59.06M | 1 | 2015-01-06 |
Recent Filings
88 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-14 | CELC | Notice (144) | −261,368 | -$26.79M | EDGAR |
| 2026-06-29 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2026-06-02 | ACAD | Grant (A) | +223,464 | $0 | EDGAR |
| 2026-05-27 | ONC | Sell (S) | −65,988 | -$1.57M | EDGAR |
| 2026-05-22 | TCRX | Grant (A) | — | $0 | EDGAR |
| 2026-05-11 | INCY | Exer (M) | +180,000 | $15.22M | EDGAR |
| 2026-04-23 | TARA | Notice (144) | −24,802 | -$132.7K | EDGAR |
| 2026-04-07 | REPL | Grant (A) | — | $0 | EDGAR |
| 2026-03-06 | TARA | Notice (144) | −38,277 | -$223.9K | EDGAR |
| 2026-03-04 | TARA | Notice (144) | −35,173 | -$220.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.